A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Robert Heller was brought in as the first editor of what became Management Today – Heseltine initially irritated him by taking him to lunch at the Carlton Club and talking of his political aspirations, but Heller soon recognised that Labovitch was the front man whose job was to impress those who needed to be impressed, and Heseltine was "the dynamic and real entrepreneurial brain". The first edition came out in April 1966, just after Heseltine's election to Parliament. Haymarket went on to publish similar magazines for Marketing, Personnel Management and Computing Institutes. Labovitch left Haymarket at the end of 1965. Heseltine stated he spent three days trying to persuade him to stay. Labovitch wanted to establish himself as a successful educational and careers publisher, and may well have been pushed by his then wife, the socialist journalist Penny Perrick, who disliked Heseltine both personally (as best man at their wedding he had, she said, welcomed various business figures in his speech as if he were at a board meeting) and politically and whom he had refused to include on the Haymarket board. Labovitch was a generator of ideas but he lacked Heseltine's business skills. Although he took his profitable Directories with him, he had to sell them back to Haymarket when his business failed in 1973, causing him to attempt suicide. Heseltine offered him a position as consultant to Haymarket. The two former partners remained on friendly terms until Labovitch's death in 1994. Very few staff left with Labovitch.
=== Microtubule stabilization === Tau proteins are found more often in neurons than in non-neuronal cells in humans. One of tau's main functions is to modulate the stability of axonal microtubules. Other nervous system microtubule-associated proteins (MAPs) may perform similar functions, as suggested by tau knockout mice that did not show abnormalities in brain development – possibly because of compensation in tau deficiency by other MAPs. Although tau is present in dendrites at low levels, where it is involved in postsynaptic scaffolding, it is active primarily in the distal portions of axons, where it provides microtubule stabilization but also flexibility as needed. Tau proteins interact with tubulin to stabilize microtubules and promote tubulin assembly into microtubules. Tau has two ways of controlling microtubule stability: isoforms and phosphorylation. In addition to its microtubule-stabilizing function, Tau has also been found to recruit signaling proteins and to regulate microtubule-mediated axonal transport.
== Production == About 200,000 tonnes of tetrahydrofuran are produced annually. The most widely used industrial process involves the acid-catalyzed dehydration of 1,4-butanediol. Ashland/ISP is one of the biggest producers of this chemical route. The method is similar to the production of diethyl ether from ethanol. The butanediol is derived from condensation of acetylene with formaldehyde followed by hydrogenation. DuPont developed a process, for producing THF by oxidizing n-butane to crude maleic anhydride, followed by catalytic hydrogenation. A third major industrial route entails hydroformylation of allyl alcohol followed by hydrogenation to 1,4-butanediol.
Directed by Sheila Hayman, made by Uden Associates 8 November Rebuilding Berlin, how German telecommunication and electrical engineers found great difficulty in connecting the infrastructure and technology of East and West Berlin, which were largely totally incompatible, and why the two technological systems were so different; East and West Germany were founded in 1953; the trains in East (Deutsche Reichsbahn or DR) and West Germany ran on electric motors that worked in opposite ways; Erich Kratky of Berliner Verkehrsbetriebe (former West Berlin Public Transport) and how East Berlin drivers had 60% of those in West Berlin; Mahlow station, on the S2 line on the Berlin S-Bahn, was completely rebuilt in 1991, opening on 31 August 1992; before 1989, West Berlin could not connect to any neighbouring electrical power networks, so had to make all of its own power itself, by nine power stations; in 1992 West Berlin could not make enough electrical power;Jürgen Beyer of the East Berlin Electricity Board; in 1992 East and West Germany could not connect their electricity systems together; Klaus Krämer of the West Berlin Electricity Board, and how East German load frequency control (LFC) was not good enough for West Germany; East German power stations were polluting; Müggelsee in East Berlin; East Berlin had natural gas - from Russia - but West Berlin did not have natural gas, and had to produce its own gas from processing, and there were many more gas leaks in East Berlin, run by the Berlin Gas Board, and British Gas plc was installing most of the new plastic gas mains in East Berlin; one fifth of housing in East Berlin was uninhabitable, due to lack of renovation and unsafe electrical wiring; much housing in East Berlin did not have any bathrooms; the post system in East Berlin was three times slower than West Berlin, as it was all sorted by hand, and mail hand to be sent in standard envelopes only, in East Germany - the two post systems were incompatible, and East and West Germany had totally different postcode systems, although both had four digits, so a letter was put in front of each Deutsche Post postcode, to show if it was an East or West German postcode; in 1952, telephone connections between East and West Germany were stopped, but four lines were installed in 1972; the East German telephone exchanges were all mechanical, and could not transmit any digital communications; one in ten people in East Berlin had a phone - telecommunications in East Berlin were hopeless and expensive; in 1992 Deutsche Telekom connected East and West Berlin, and the price would be a local call, not the price of an international call, under the phrase Wir schaffen Verbingdungen; not only were East German telecommunications often impossible, but the Stasi secret police were listening in to most calls; Rudolf Reichel of the former East German Economic Institute; science research in East Germany had been greatly restricted; Volker Hassemer; East Germans viewed West Germans as selfish, and West Germans viewed East Germans as backward. Narrated by Su-Lin Looi, directed by Cosima Dannoritzer, produced by Karl Sabbagh, made by Skyscraper Productions 15 November 21st Century Jet, how the Boeing 777 moved from the drawing board to manufacture in 1992, with the innovative new method called CATIA; the Boeing 777 was the largest jet aircraft to have been developed mostly by computer, with assembly beginning in January 1993; there were 10,000 people in the 777 programme, who met the managers in a weekly meeting; meeting the needs of Robert Crandall of American Airlines, and competition from the new Airbus A340; parts of the tail were built in Australia; the nose cone and flaps were made in Italy; the landing gear was made in Canada, the US, and France; parts of the wing ribs and passenger doors were made in Japan; the nose landing gear door was made in Belfast; some of the electronics was made in England; there were about 230 design teams, from different manufacturers; the CATIA system was a digital mockup; Thomas Gaffney, head of passenger doors; Henry Shomber, one of the chief engineers; John Roundhill, a chief project engineer; United Airlines placed the first order, which started the project; Al Tyler of Aerospace Technologies of Australia (ASTA), who made the 777 rudder - the company became Boeing Australia; John King, Baron King of Wartnaby of British Airways visits to look at legroom for the new 777. Narrated by Simon Prebble, directed by Karl Sabbagh, made by Skyscraper Productions 22 November The Puzzle of HIV, scientists after ten years did not understand how HIV worked; immunologists Anthony Fauci and Max Essex; Angus Dalgleish of St George's, University of London; virologist Stephen S. Morse, and the origination of viruses, and how most pandemics originated in China; Stella Knight of the MRC, and dendritic cells, researched by Brigid Balfour; French immunologist Jean-Claude Ameisen of the Pasteur Institute of Lille; virologist Jonas Salk; Claude Nicolau, and the CD4 glycoprotein. Narrated by Scottish actress Sandra Clark, directed by Nigel Maslin, produced by Chris Haws, made by InCA Productions 29 November The Alpha Link, much of medical understanding of radiation protection and health comes from what occurred in Japan in August 1945. Martin Gardner (1940–93), an epidemiologist, and Professor of Medical Statistics at the University of Southampton, thought that health was affected by working in a nuclear power station, which the British nuclear industry vehemently would not believe. Directed by Vivienne King, made by Box Productions 6 December Toying with the Future, about electronic children's toys, visiting Ocean Software in Manchester; Brian Sutton-Smith of the University of Pennsylvania, and how toys were small replicas of large world events; Eugene F. Provenzo of the University of Miami and how the culture of childhood began in the early 1700s, and how German Friedrich Fröbel developed educational toys in the early 1800s, but it often lacked fun; Meccano Ltd sets, developed by Frank Hornby, launching the international Meccano Guild network of children's mechanical clubs in 1919, publicised by the Meccano Magazine; Richard Gregory, neuropsychologist at the University of Bristol, and his Exploratory Hands-on Science Centre, which closed in 1999, replaced by We the Curious in 2000; toy designer Patrick Rylands; Gary Bracey of Ocean Software; Keith Tinman, computer game musician; Elizabeth Curran of GameTek; Ocean Software designers Ray Coffey, James Higgins and Dawn Drake. Directed by Christopher Rawlence, produced by Debra Hauer, made by Rawlence Hauer Productions 13 December The Elements, a repeat of the 20 October 1991 episode 20 December E.T. Please Phone Earth, about the SETI Institute, with Prof Philip Morrison, a professor of physics at MIT, who played a starring if not dangerous role in the Manhattan Project; Jill Tarter at the Hat Creek Radio Observatory in California; Dr John Billingham, a British medical doctor at the Ames Research Center in California; Prof Antony Hewish of the University of Cambridge, who discovered pulsars in 1967; Frank Drake, and his work at the National Radio Astronomy Observatory in Green Bank, West Virginia; Barney Oliver of SETI; David Blair of the University of Western Australia; Paul Horowitz of Harvard University; the Ohio State University Radio Observatory (known as Big Ear) and its 1977 Wow! signal; Jack Cohen; chemist Stanley Miller and his 1953 experiment; blind SETI investigator Kent Cullers; and biologist Jared Diamond from UCLA. Jointly made with ABC of Australia, narrated by Heather Couper, directed by Richard Smith, produced by Stuart Carter, made by Pioneer Productions
Sources: en.wikipedia.org
Dispensing practice Cautionary Advisory Labels (CALs) information and recommendations Good compounding practice Compounding sterile and hazardous medicines Extemporaneous formulary Cold chain management Clinical drug monographs Information on complementary medicines Counseling guides for common ailments National pharmacy standards and guidelines, and Physicochemical data of drug constituents.
In 1992, DiCaprio had a brief role in the first installment of the Poison Ivy film series, and was handpicked by Robert De Niro from a shortlist of 400 young actors to co-star with him in This Boy's Life. Adapted from the memoir by Tobias Wolff, the film focuses on the relationship between a rebellious teenager, Toby (DiCaprio), and his mother (Ellen Barkin) and abusive stepfather (De Niro). Director Michael Caton-Jones said that DiCaprio did not know how to behave on set; accordingly, Caton-Jones used a strict mentoring style, after which DiCaprio's behavior began to improve. Bilge Ebiri of Rolling Stone found that the powerful bond between Barkin and DiCaprio elevated the film, praising DiCaprio's portrayal of his character's complex growth from a rebellious teen to an independent young man. This Boy's Life was the first film that gained him recognition. DiCaprio's first talk show appearance was in 1992 on the Looseleaf Report, hosted by Victoria Looseleaf, who later wrote a 1998 (unauthorized) biography on him. DiCaprio played the developmentally disabled brother of Johnny Depp's character in What's Eating Gilbert Grape (1993), a comedy-drama about a dysfunctional Iowa family. Caton-Jones recommended DiCaprio to director Lasse Hallström who was initially skeptical, as he considered DiCaprio too good-looking for the part. Hallström cast DiCaprio after he emerged as "the most observant" auditionee.
The subject was said to have “agrypnia excitata”, which consists of severe total insomnia of long duration associated with decreased vigilance, mental confusion, hallucinations, motor agitation, and complex motor behavior mimicking dreams, and autonomic activation. CNS and autonomic symptoms were caused by impaired corticolimbic control of the subcortical structures regulating the sleep-wake and autonomic functions.
Deuterium is produced for industrial, scientific and military purposes, by starting with ordinary water—a small fraction of which is naturally occurring heavy water—and then separating out the heavy water by the Girdler sulfide process, distillation, or other methods. In theory, deuterium for heavy water could be created in a nuclear reactor, but separation from ordinary water is the cheapest bulk production process. The world's leading supplier of deuterium was Atomic Energy of Canada Limited until 1997, when the last heavy water plant was shut down. Canada uses heavy water as a neutron moderator for the operation of the CANDU reactor design. Another major producer of heavy water is India. All but one of India's atomic energy plants are pressurized heavy water plants, which use natural (i.e., not enriched) uranium. India has eight heavy water plants, of which seven are in operation. Six plants, of which five are in operation, are based on D–H exchange in ammonia gas. The other two plants extract deuterium from natural water in a process that uses hydrogen sulfide gas at high pressure. While India is self-sufficient in heavy water for its own use, India also exports reactor-grade heavy water.
== Background == Shelf life is the recommended maximum time for which products or fresh (harvested) produce can be stored, during which the defined quality of a specified proportion of the goods remains acceptable under expected (or specified) conditions of distribution, storage and display. According to the United States Department of Agriculture (USDA), most "canned foods are safe indefinitely as long as they are not exposed to freezing temperatures, or temperatures above 90 °F (32.2 °C)". Not all canned goods are shelf-stable and those labeled "keep refrigerated" are not safe to store at room temperature. Rusted, swollen and dented cans may not be safe for consumption. Over time, most notably for high acid foods such as tomatoes, food stored in cans will change in taste and texture and will eventually have lowered nutritional value. "Sell by date" is a less ambiguous term for what is often referred to as an "expiration date". Most food is still edible after the expiration date. A product that has passed its shelf life might still be safe, but quality is no longer guaranteed. In most food stores, waste is minimized by using stock rotation, which involves moving products with the earliest sell by date from the warehouse to the sales area, and then to the front of the shelf, so that most shoppers will pick them up first and thus they are likely to be sold before the end of their shelf life. Some stores can be fined for selling out of date products; most if not all would have to mark such products down as wasted, resulting in a financial loss.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.